Literature DB >> 8517015

The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.

J J Schlesinger1, M Foltzer, S Chapman.   

Abstract

The mechanism by which antibodies to the flavivirus nonvirion protein NS1 protect mice against encephalitis is unknown but their binding to cell surface NS1 raises the possibility of involvement of an Fc piece-directed immune function. To investigate this, we prepared the F(ab')2 moiety of a protective IgG2a monoclonal antibody (Mab) against yellow fever virus (YF) NS1 and isolated IgG2a- and IgG2b-secreting isotype switch variants from a hybridoma that secretes a nonprotective IgG1 anti-YF NS1 Mab. Each Mab, complexed to NS1, bound to macrophage Fc receptor (FcR) but only the IgG2a and IgG2b Mabs sensitized YF-infected cells to complement-mediated cytolysis. Passively transferred IgG2a Mabs, but not F(ab')2, IgG1, or IgG2b Mabs, interfered with replication of YF in mouse brain. IgG2a Mabs protected mice against YF encephalitis but passive transfer of a mixture of variant IgG2a and parent IgG1 Mabs, or of unrelated IgG2a and IgG1 Mabs directed at the same NS1 epitope, resulted in markedly reduced protection, findings that may bear on flavivirus vaccine design. IgG2a Mab interfered with CNS YF replication in, and protected, C3-depleted mice, but not mice treated with high-dose cyclophosphamide to eliminate antibody-dependent killer cell activity. Taken together, these results indicate that epitope specificity alone may be inadequate to account for protection by anti-NS1 antibody and are consistent with involvement of an FcR-dependent protective mechanism that is governed by antibody isotype.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517015     DOI: 10.1006/viro.1993.1015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  68 in total

1.  Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody.

Authors:  Bimmi Shrestha; S Kyle Austin; Kimberly A Dowd; Abhishek N Prasad; Soonjeon Youn; Theodore C Pierson; Daved H Fremont; Gregory D Ebel; Michael S Diamond
Journal:  Virology       Date:  2012-03-09       Impact factor: 3.616

2.  A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition.

Authors:  Soonjeon Youn; Hyelim Cho; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 3.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

4.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Authors:  Laurent Gros; Hanna Dreja; Anne Laure Fiser; Marc Plays; Mireia Pelegrin; Marc Piechaczyk
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Kyung Min Chung; Grant E Nybakken; Bruce S Thompson; Michael J Engle; Anantha Marri; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 7.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

8.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

9.  Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.

Authors:  T R Kreil; E Maier; S Fraiss; M M Eibl
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

10.  Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation.

Authors:  I R Muylaert; R Galler; C M Rice
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.